# EDGAR Filing Document

**Accession Number:** 0000714256
**File Stem:** 0001493152-26-003316
**Filing Date:** 2026-1
**Character Count:** 15490
**Document Hash:** 7f83a8c83d1823f1a02776573d9d8b50
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-003316.hdr.sgml**: 20260123

**ACCESSION NUMBER**: 0001493152-26-003316

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260123

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260123

**DATE AS OF CHANGE**: 20260123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sanara MedTech Inc.
- **CENTRAL INDEX KEY:** 0000714256
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 592220004
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39678
- **FILM NUMBER:** 26553350

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 SUMMIT AVE
- **STREET 2:** SUITE 414
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76102
- **BUSINESS PHONE:** 817-529-2300

**MAIL ADDRESS:**
- **STREET 1:** 1200 SUMMIT AVE
- **STREET 2:** SUITE 414
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WOUND MANAGEMENT TECHNOLOGIES, INC.
- **DATE OF NAME CHANGE:** 20080611

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MB SOFTWARE CORP
- **DATE OF NAME CHANGE:** 19960805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INAV TRAVEL CORPORATION
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 23, 2026**

**SANARA MEDTECH INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Texas** | **001-39678** | **59-2219994** |
| (State or other jurisdiction of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **1200 Summit Avenue, Suite 414** <br> **Fort Worth, Texas** | **76102** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(817) 529-2300**

(Former name or former address, if changed since last report)

**Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading** <br> **Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value | SMTI | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02** **Results of Operations and Financial Condition.**

On January 23, 2026, Sanara MedTech Inc. (the "Company") issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2025. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

**Item 9.01** **Financial Statements and Exhibits.**

**(d) Exhibits** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release issued January 23, 2026 (furnished pursuant to Item 2.02).](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 23, 2026 |  |  |
|  | **Sanara MedTech Inc**. | **Sanara MedTech Inc**. |
|  | By: | /*s/ Elizabeth B. Taylo*r |
|  |  | Name: Elizabeth B. Taylor |
|  |  | Title: Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance** 

**FORT WORTH, TX, January 23, 2026 (GLOBE NEWSWIRE) –** Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year ending December 31, 2026.

**Selected Fourth Quarter and Full Year 2025 Preliminary Financial Results (Unaudited):**

● Net revenue for the fourth quarter of 2025 is expected to be in the range of $27.2 million to $27.7 million, an increase of approximately 3% to 5%, compared to $26.3 million in the fourth quarter of 2024.

○ As previously disclosed, the Company experienced growth in sales of BIASURGE<sup>®</sup> Advanced Surgical Solution ("BIASURGE") in the fourth quarter of 2024, as a result of supply chain issues and shortages of intravenous fluids and saline solutions experienced by the broader industry due to Hurricane Helene. Excluding approximately $1.8 million of BIASURGE sales in the fourth quarter of 2024, net revenue in the fourth quarter of 2025 is expected to increase approximately 11% to 13% year-over-year.<sup>(1)</sup>

● Net revenue for the full year 2025 is expected to be in the range of $102.7 million to $103.2 million, an increase of approximately 19%, compared to $86.7 million for the full year 2024.

○ Excluding the aforementioned $1.8 million of BIASURGE sales in the fourth quarter 2024, net revenue for the full year 2025 is expected to increase approximately 21% to 22% year-over-year.<sup>(1)</sup>

● As of December 31, 2025, the Company had cash of approximately $16.6 million and long-term debt of $46.0 million, compared to cash of $15.9 million and long-term debt of $30.7 million as of December 31, 2024.

**Fourth Quarter and Recent Operational Highlights:**

● On December 10, 2025, the Company provided an update on progress related to its strategic alliance with Biomimetic Innovations Ltd ("BMI"). In addition, Sanara reaffirmed its plans to introduce the OsStic<sup>™</sup> Synthetic Injectable Structural Bio-Adhesive ("OsStic") to the U.S. commercial market in the first quarter of 2027, following anticipated clearance by the U.S. Food and Drug Administration, to support reduction and provisional fixation treatment of the more than 100,000<sup>(2)</sup> peri-articular fractures occurring annually nationwide.

● On January 07, 2026, the Company announced its BIASURGE product received an Innovative Technology contract from Vizient, Inc. ("Vizient"), the nation's largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of BIASURGE by hospital experts who serve on one of Vizient's client-led councils, and it signifies to Vizient clients BIASURGE's unique qualities that potentially bring improvement to the healthcare industry. The Innovative Technology contract offers Vizient's extensive network of healthcare facility customers access to BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026.

**Full Year 2026 Financial Guidance:**

● The Company expects full year 2026 net revenue to range from $116 million to $121 million, representing growth of approximately 13% to 17%, compared to the midpoint of the expected net revenue range for the full year 2025.

"Our team delivered strong performance in 2025, culminating in preliminary net revenue of approximately $103 million, an increase of approximately 19% year-over-year," stated Seth Yon, Sanara's President and Chief Executive Officer. "In the fourth quarter of 2025, our preliminary net revenue increased in the range of 11% to 13% year-over-year, excluding approximately $1.8 million of BIASURGE sales in the prior year period, consistent with the range of expectations shared on our Q3 earnings call.<sup>(1)</sup> Operationally, we made important progress across multiple areas during the fourth quarter. Importantly, we secured a new contract with Vizient, Inc. – the largest group purchasing organization in the U.S. – which significantly expands access to BIASURGE at contracted pricing and pre-negotiated terms. In addition, we enhanced our sales and distribution network, while also working to expand our product portfolio through our initiatives with BMI related to OsStic."

Mr. Yon continued: "Looking ahead to 2026, we expect to deliver net revenue growth of approximately 13% to 17% year-over-year, fueled primarily by sales of our soft tissue products. We are entering 2026 as a pure play surgical business for the treatment of surgical wounds, which we believe positions Sanara to deliver sustainable, long-term growth and profitability as we expand our share of the multi-billion-dollar surgical solutions market."

The Company's independent registered public accounting firm has not completed its procedures with respect to the preliminary financial information or its audit of our financial statements for the year ended December 31, 2025. Actual results may differ from these estimates as a result of the completion of our audit and other developments that may arise between now and the time our financial results for the fourth quarter and fiscal year are finalized.

<sup>(1)</sup> *Net revenue excluding BIASURGE sales in the fourth quarter of 2024 is a non-GAAP financial measure. See the discussion and the reconciliations at the end of this release for additional information*.

<sup>(2)</sup> *National Library of Medicine; BMI and Sanara company estimates*.

**About Sanara MedTech Inc.**

Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets, and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company's products, services, and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara's products are primarily sold in the North American surgical tissue repair markets. Sanara markets and distributes CellerateRX<sup>®</sup> Surgical Activated Collagen<sup>®</sup> Powder, BIASURGE<sup>®</sup> Advanced Surgical Solution, FORTIFY TRG<sup>®</sup> Tissue Repair Graft, FORTIFY FLOWABLE<sup>®</sup> Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN<sup>®</sup> Verified Inductive Bone Matrix, ALLOCYTE<sup>®</sup> Plus Advanced Viable Bone Matrix, BiFORM<sup>®</sup> Bioactive Moldable Matrix, and TEXAGEN<sup>®</sup> Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.

**Information about Forward-Looking Statements**

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

**Investor Relations Contact:**

Jack Powell or Mike Piccinino, CFA

ICR Healthcare

IR@sanaramedtech.com

**SANARA MEDTECH INC. AND SUBSIDIARIES**

**NON-GAAP FINANCIAL MEASURES (UNAUDITED)**

To supplement the Company's financial information presented in accordance with generally accepted accounting principles in the United States ("GAAP"), we present adjusted net revenue, a non-GAAP financial measure, in this press release, which adjusts net revenue for unusual events, including the $1.8 million of sales of BIASURGE in the fourth quarter of 2024, as a result of supply chain issues and shortages of intravenous fluids and saline solutions experienced by the broader industry due to Hurricane Helene. The Company's non-GAAP financial measures are not in accordance with, nor an alternative for, measures conforming to GAAP and may be different from non-GAAP financial measures used by other companies.

**Reconciliation of Net Revenue to Adjusted Net Revenue:**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **($ in millions)** | | | | | | | | | | |
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | | | **Twelve Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** | | |
|  | **December 31,** | **December 31,** | **December 31,** | **% Increase** | **% Increase** | **December 31,** | **December 31,** | **December 31,** | **% Increase** | **% Increase** |
|  | **2025** | **2025** | **2024** |  |  | **2025** | **2025** | **2024** |  |  |
|  | **Low** | **High** |  | **Low** | **High** | **Low** | **High** |  | **Low** | **High** |
| **Net Revenue** | $27.2 | $27.7 | $26.3 | 3% | 5% | $102.7 | $103.2 | $86.7 | 19% | 19% |
| **BIASURGE sales <sup>(1)</sup>** |  | - | (1.8) |  |  |  | - | (1.8) |  |  |
| **Adjusted Net Revenue (excluding BIASURGE sales)** | $27.2 | $27.7 | $24.5 | 11% | 13% | $102.7 | $103.2 | $84.8 | 21% | 22% |

---

(1) Estimated BIASURGE sales related to supply chain issues and shortages of intravenous fluids and saline solutions experienced by the broader industry during the fourth quarter of 2024 due to Hurricane Helene.